For the Inventor, By the Inventor

Enter assignee name

Pasadena, CA, United States of America

Xencor, Inc.

USPTO Granted Patents = 228

% Expired Patents = 7.0

CIPO Patents = 14

EPO Patents = 53

Trademarks = 5

Forward Citations = 3,848

Loading Chart...

Loading Chart...

109 inventors (with patents filed for the assignee):

John R Desjarlais (177 out of 178 patents)

Matthew J Bernett (103 out of 105 patents)

Gregory Alan Lazar (89 out of 99 patents)

4. Gregory L Moore (84 out of 85 patents)

5. Sher Bahadur Karki (70 out of 70 patents)

6. Rumana Rashid (56 out of 56 patents)

7. Seung Yup Chu (54 out of 54 patents)

8. Omid Vafa (33 out of 37 patents)

9. Wei Dang (32 out of 32 patents)

10. Robert J Hayes (32 out of 33 patents)

11. Bassil I Dahiyat (31 out of 38 patents)

12. Umesh Muchhal (26 out of 27 patents)

13. Rajat Varma (23 out of 23 patents)

14. Arthur J Chirino (20 out of 20 patents)

15. Michael Hedvat (19 out of 19 patents)

Core Competencies:

Heterodimeric Antibodies

Fc Fusion Proteins

CD3 Targeting

PSMA Binding

IL-15

Bispecific Antibodies

CTLA4-IG

Immunotherapy

Checkpoint Inhibitors

IgE-Mediated Disorders

Neurological Diseases

Optimized Fc Variants

228 patents: Sort by Forward Citations

1. 12760119 - HETERODIMERIC ANTIBODIES THAT BIND ENPP3 AND CD3 (2026-10-13),

2. 12703748 - Anti-CD28 compositions (2026-08-11),

3. 12698341 - ANTIGEN BINDING DOMAINS THAT BIND TO MESOTHELIN (MSLN) (2026-08-04),

4. 12655230 - HETERODIMERIC ANTIBODIES THAT BIND CD3 AND GPC3 (2026-06-16),

5. 12617872 - HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS (2026-05-05),

6. 12559572 - NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS (2026-02-24),

7. 12509518 - METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASES (2025-12-30),

8. 12509495 - LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS (2025-12-30),

9. 12497457 - METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASES (2025-12-16),

10. 12492253 - ANTI-HUMAN C5 ANTIBODIES (2025-12-09),

11. 12486311 - NOVEL CTLA4-IG IMMUNOADHESINS (2025-12-02),

12. 12466897 - HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS (2025-11-11),

13. 12448423 - Targeted heterodimeric Fc fusion proteins containing NKG2D antigen binding domains (2025-10-21),

14. 12415849 - Heterodimeric proteins (2025-09-16),

15. 12404329 - Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 (2025-09-02),

Company Overview

Xencor, Inc., based in Pasadena, California, specializes in the development of innovative therapies utilizing heterodimeric antibodies and Fc fusion proteins. The company focuses on advancing immunotherapy solutions, particularly through its expertise in bispecific antibodies and targeted therapies that engage the immune system. Key areas of research include CD3 targeting, PSMA binding, and the application of IL-15 and CTLA4-IG in therapeutic contexts, positioning Xencor at the forefront of next-generation cancer treatments.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

228 Patents

#2 in Pasadena, CA

#397 in California

#1,838 in US

#3,758 in the World

Pasadena, CA, United States of America

Xencor, Inc.

Forward Citations = 3,848

109 inventors:

John R Desjarlais (177 out of 178 patents)

Matthew J Bernett (103 out of 105 patents)

Gregory Alan Lazar (89 out of 99 patents)

4. Gregory L Moore (84 out of 85 patents)

5. Sher Bahadur Karki (70 out of 70 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Xencor, Inc.. Retrieved from https://idiyas.com/company/xencor

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…